Heritage Investors Management Corp Sells 650 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Heritage Investors Management Corp reduced its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 1.2% in the third quarter, Holdings Channel reports. The fund owned 54,130 shares of the company’s stock after selling 650 shares during the quarter. Heritage Investors Management Corp’s holdings in Teva Pharmaceutical Industries were worth $975,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of TEVA. New Covenant Trust Company N.A. bought a new stake in Teva Pharmaceutical Industries in the first quarter worth $28,000. EntryPoint Capital LLC bought a new stake in Teva Pharmaceutical Industries in the first quarter worth $30,000. UMB Bank n.a. lifted its position in Teva Pharmaceutical Industries by 555.6% in the third quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock worth $44,000 after buying an additional 2,067 shares during the last quarter. Beach Investment Counsel Inc. PA bought a new stake in Teva Pharmaceutical Industries in the second quarter worth $48,000. Finally, Byrne Asset Management LLC bought a new stake in Teva Pharmaceutical Industries in the second quarter worth $52,000. 54.05% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. JPMorgan Chase & Co. increased their target price on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research note on Monday, October 21st. UBS Group increased their target price on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a research note on Tuesday, September 3rd. Barclays increased their target price on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 23rd. Argus upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 target price on the stock in a research note on Wednesday, July 10th. Finally, StockNews.com upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $19.67.

Teva Pharmaceutical Industries Stock Performance

Shares of Teva Pharmaceutical Industries stock opened at $18.78 on Wednesday. The company has a debt-to-equity ratio of 2.52, a quick ratio of 0.59 and a current ratio of 0.89. Teva Pharmaceutical Industries Limited has a 12 month low of $8.55 and a 12 month high of $19.08. The stock’s fifty day moving average price is $18.03 and its 200-day moving average price is $17.06.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.